Cargando…

The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury

BACKGROUND: Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few eCB compounds while largely ignoring the complexity of the eCB system. We exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Vered, Shiraz, Beiser, Alexa S., Sulimani, Liron, Sznitman, Sharon, Gonzales, Mitzi M., Aparicio, Hugo J., DeCarli, Charles, Scott, Matthew R., Ghosh, Saptaparni, Lewitus, Gil M., Meiri, David, Seshadri, Sudha, Weinstein, Galit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496329/
https://www.ncbi.nlm.nih.gov/pubmed/37700370
http://dx.doi.org/10.1186/s13195-023-01301-x
_version_ 1785105083014316032
author Vered, Shiraz
Beiser, Alexa S.
Sulimani, Liron
Sznitman, Sharon
Gonzales, Mitzi M.
Aparicio, Hugo J.
DeCarli, Charles
Scott, Matthew R.
Ghosh, Saptaparni
Lewitus, Gil M.
Meiri, David
Seshadri, Sudha
Weinstein, Galit
author_facet Vered, Shiraz
Beiser, Alexa S.
Sulimani, Liron
Sznitman, Sharon
Gonzales, Mitzi M.
Aparicio, Hugo J.
DeCarli, Charles
Scott, Matthew R.
Ghosh, Saptaparni
Lewitus, Gil M.
Meiri, David
Seshadri, Sudha
Weinstein, Galit
author_sort Vered, Shiraz
collection PubMed
description BACKGROUND: Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few eCB compounds while largely ignoring the complexity of the eCB system. We examined the associations of multiple circulating eCBs and eCB-like molecules with early markers of neurodegeneration and neuro-injury and tested for effect modification by sex. METHODS: This exploratory cross-sectional study included a random sample of 237 dementia-free older participants from the Framingham Heart Study Offspring cohort who attended examination cycle 9 (2011–2014), were 65 years or older, and cognitively healthy. Forty-four eCB compounds were quantified in serum, via liquid chromatography high-resolution mass spectrometry. Linear regression models were used to examine the associations of eCB levels with brain MRI measures (i.e., total cerebral brain volume, gray matter volume, hippocampal volume, and white matter hyperintensities volume) and blood biomarkers of Alzheimer’s disease and neuro-injury (i.e., total tau, neurofilament light, glial fibrillary acidic protein and Ubiquitin C-terminal hydrolase L1). All models were adjusted for potential confounders and effect modification by sex was examined. RESULTS: Participants mean age was 73.3 ± 6.2 years, and 40% were men. After adjustment for potential confounders and correction for multiple comparisons, no statistically significant associations were observed between eCB levels and the study outcomes. However, we identified multiple sex-specific associations between eCB levels and the various study outcomes. For example, high linoleoyl ethanolamide (LEA) levels were related to decreased hippocampal volume among men and to increased hippocampal volume among women (β ± SE =  − 0.12 ± 0.06, p = 0.034 and β ± SE = 0.08 ± 0.04, p = 0.026, respectively). CONCLUSIONS: Circulating eCBs may play a role in neuro-injury and may explain sex differences in susceptibility to accelerated brain aging. Particularly, our results highlight the possible involvement of eCBs from the N-acyl amino acids and fatty acid ethanolamide classes and suggest specific novel fatty acid compounds that may be implicated in brain aging. Furthermore, investigation of the eCBs contribution to neurodegenerative disease such as Alzheimer’s disease in humans is warranted, especially with prospective study designs and among diverse populations, including premenopausal women. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01301-x.
format Online
Article
Text
id pubmed-10496329
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104963292023-09-13 The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury Vered, Shiraz Beiser, Alexa S. Sulimani, Liron Sznitman, Sharon Gonzales, Mitzi M. Aparicio, Hugo J. DeCarli, Charles Scott, Matthew R. Ghosh, Saptaparni Lewitus, Gil M. Meiri, David Seshadri, Sudha Weinstein, Galit Alzheimers Res Ther Research BACKGROUND: Preclinical studies highlight the importance of endogenous cannabinoids (endocannabinoids; eCBs) in neurodegeneration. Yet, prior observational studies focused on limited outcome measures and assessed only few eCB compounds while largely ignoring the complexity of the eCB system. We examined the associations of multiple circulating eCBs and eCB-like molecules with early markers of neurodegeneration and neuro-injury and tested for effect modification by sex. METHODS: This exploratory cross-sectional study included a random sample of 237 dementia-free older participants from the Framingham Heart Study Offspring cohort who attended examination cycle 9 (2011–2014), were 65 years or older, and cognitively healthy. Forty-four eCB compounds were quantified in serum, via liquid chromatography high-resolution mass spectrometry. Linear regression models were used to examine the associations of eCB levels with brain MRI measures (i.e., total cerebral brain volume, gray matter volume, hippocampal volume, and white matter hyperintensities volume) and blood biomarkers of Alzheimer’s disease and neuro-injury (i.e., total tau, neurofilament light, glial fibrillary acidic protein and Ubiquitin C-terminal hydrolase L1). All models were adjusted for potential confounders and effect modification by sex was examined. RESULTS: Participants mean age was 73.3 ± 6.2 years, and 40% were men. After adjustment for potential confounders and correction for multiple comparisons, no statistically significant associations were observed between eCB levels and the study outcomes. However, we identified multiple sex-specific associations between eCB levels and the various study outcomes. For example, high linoleoyl ethanolamide (LEA) levels were related to decreased hippocampal volume among men and to increased hippocampal volume among women (β ± SE =  − 0.12 ± 0.06, p = 0.034 and β ± SE = 0.08 ± 0.04, p = 0.026, respectively). CONCLUSIONS: Circulating eCBs may play a role in neuro-injury and may explain sex differences in susceptibility to accelerated brain aging. Particularly, our results highlight the possible involvement of eCBs from the N-acyl amino acids and fatty acid ethanolamide classes and suggest specific novel fatty acid compounds that may be implicated in brain aging. Furthermore, investigation of the eCBs contribution to neurodegenerative disease such as Alzheimer’s disease in humans is warranted, especially with prospective study designs and among diverse populations, including premenopausal women. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01301-x. BioMed Central 2023-09-12 /pmc/articles/PMC10496329/ /pubmed/37700370 http://dx.doi.org/10.1186/s13195-023-01301-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vered, Shiraz
Beiser, Alexa S.
Sulimani, Liron
Sznitman, Sharon
Gonzales, Mitzi M.
Aparicio, Hugo J.
DeCarli, Charles
Scott, Matthew R.
Ghosh, Saptaparni
Lewitus, Gil M.
Meiri, David
Seshadri, Sudha
Weinstein, Galit
The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
title The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
title_full The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
title_fullStr The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
title_full_unstemmed The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
title_short The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
title_sort association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496329/
https://www.ncbi.nlm.nih.gov/pubmed/37700370
http://dx.doi.org/10.1186/s13195-023-01301-x
work_keys_str_mv AT veredshiraz theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT beiseralexas theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT sulimaniliron theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT sznitmansharon theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT gonzalesmitzim theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT apariciohugoj theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT decarlicharles theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT scottmatthewr theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT ghoshsaptaparni theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT lewitusgilm theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT meiridavid theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT seshadrisudha theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT weinsteingalit theassociationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT veredshiraz associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT beiseralexas associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT sulimaniliron associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT sznitmansharon associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT gonzalesmitzim associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT apariciohugoj associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT decarlicharles associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT scottmatthewr associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT ghoshsaptaparni associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT lewitusgilm associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT meiridavid associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT seshadrisudha associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury
AT weinsteingalit associationofcirculatingendocannabinoidswithneuroimagingandbloodbiomarkersofneuroinjury